Stamin

Quick links to important sections

Stamin

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stamin

Quick Facts

Property Description
Active ingredient Piracetam (2-oxo-1-pyrrolidine acetamide)
Form Tablet, Capsule, Oral Solution, Solution for Injection
Pharmacological class Nootropic Drug (Racetam derivative)
Common use Cognitive enhancer, Neuroprotection
Origin Synthetic compound

What is Stamin? Definition and Pharmacological Class

Stamin is a prescription-only medication (POM) that serves as a trade name for the synthetic compound Piracetam. This medication is classified as the original member of the nootropic drug class, positioning it as a cerebroactive agent that acts upon the Central Nervous System (CNS). Piracetam is structurally a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA), and it established the prototype for the Racetam chemical family. Stamin is distinguished by offering the single active ingredient Piracetam across several versatile forms, characterized by its specific mechanism in neuronal function.

Composition, Forms, and General Therapeutic Purpose

The active ingredient is supplied in multiple pharmaceutical preparations, including oral tablets and capsules, an oral solution in an aqueous base, and a sterile solution for injection (ampoule) for parenteral administration. This variety ensures appropriate delivery based on clinical need. Piracetam's high-level general purpose is to function as a cognitive enhancer by optimizing cerebral performance. The drug's action includes the restoration of cell membrane fluidity and the facilitation of microcirculation in the brain. This clinically recognized property means the medication can help the brain's cells communicate more efficiently and protect them from certain stresses. The drug's physiological actions involve the modulation of neuronal plasticity and stabilization of neuronal membranes, which supports fundamental cognitive processes, including attention, memory, and learning capacity, for which it is commonly used.

What side effects are possible with Stamin?

Possible Side Effects and Safety Information

The official safety profile for Stamin (Piracetam) organizes potential adverse effects and limitations based strictly on frequency categories and organ system classifications documented in regulatory sources.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by the estimated frequency of occurrence, as listed in the Summary of Product Characteristics (SmPC) and similar regulatory documents:

Classification Examples of Documented Effects
Common (1 to 10 in 100 users) Nervousness, Hyperkinesia (increased movement), Weight increase.
Uncommon (1 to 10 in 1,000 users) Somnolence (drowsiness), Asthenia (weakness).
Not Known (Cannot be estimated) Depression, anxiety, confusion, hallucination, dizziness, gastrointestinal symptoms, skin reactions, and Anaphylactoid reaction.

These effects are generally classified within System-Organ Classes such as Psychiatric disorders, Nervous system disorders, and Gastrointestinal disorders.

Serious Reactions and Safety Constraints

The regulatory safety profile notes the potential for Anaphylactoid reaction, a severe allergic event. High-level safety constraints apply due to the substance's documented anti-aggregant effect on platelets. Consequently, the use of Stamin is explicitly contraindicated in individuals who have experienced cerebral haemorrhage and those with severe renal impairment (end-stage renal disease).

Population and Duration-Related Safety Notes

Specific safety considerations are documented for certain populations: Dose adjustment is required for individuals with renal impairment, and monitoring of renal function is advised for older adults. Furthermore, abruptly stopping treatment, particularly in patients managing myoclonus, carries the documented risk of aggravating the myoclonus or provoking seizures. This safety structure formally defines the regulatory boundaries and documented risks associated with the medicine's use.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented information regarding Stamin overdose, strictly derived from authoritative governmental regulatory documents ( e.g., FDA, EMA).

Documented Overdose Manifestations and Risks

Overdose presentations typically include gastrointestinal disturbances (such as nausea and vomiting) and musculoskeletal symptoms ( e.g., myalgia or muscle weakness). Laboratory findings often show elevated serum Creatine Kinase (CK). The most serious and life-threatening outcome documented is Rhabdomyolysis, which carries a risk of resulting in Acute Renal Failure.

Emergency Actions and Management

Regulatory information mandates the immediate discontinuation of Stamin upon suspicion of an overdose. Treatment is primarily symptomatic and supportive. There is no specific antidote listed in the official prescribing information. Supportive measures may include monitoring and management of complications, often emphasizing adequate hydration to mitigate renal damage.

Urgent medical attention is required for any suspected overdose or if symptoms of Rhabdomyolysis ( e.g., severe muscle pain, dark urine) occur. Patients are instructed to immediately contact a physician, emergency services, or a Poison Control Center (PCC) for procedural guidance and clinical observation.

Therapeutic Uses of Stamin

What Stamin Treats: Main Uses and Benefits


The therapeutic profile of Stamin (Piracetam) is primarily focused on the supportive management of specific neurological and cognitive conditions.

Controlling Involuntary Muscle Jerks and Specific Movement Disorders

Stamin is considered relevant for managing involuntary muscular contractions known as myoclonus, particularly in contexts like Progressive Myoclonus Epilepsy. This medication is applied in addressing these symptoms of increased neurological or muscular activity, which may help patients cope more steadily with symptom fluctuations and assists with maintaining functional stability for the patient.

The primary therapeutic domains include cortical myoclonus, vertigo, and certain cognitive disorders. The intended benefit is to offer symptomatic support that helps maintain a sense of stability when symptoms are more noticeable.

Supporting Cognitive Function and Balance

The medication is commonly used to help with specific symptoms related to systemic imbalance and cognitive functioning. This includes managing symptom clusters that interfere with daily comfort related to difficulties with attention, short-term memory, and concentration in appropriate contexts. It is further applied in addressing chronic or recurrent vertigo and associated feelings of disequilibrium. This supports patients during episodes of heightened discomfort and may help maintain a sense of stability when symptoms are more noticeable. For certain specific learning difficulties, such as developmental dyslexia in children, its use may be part of symptomatic management applied in addressing symptom clusters that interfere with daily comfort, such as difficulties with verbal learning and comprehension.


Quick Fact: Symptomatic Relief Domains Stamin is commonly applied in scenarios where symptoms related to systemic imbalance create noticeable functional strain, helping to manage recurrent or episodic manifestations like vertigo and assisting with symptoms of increased neurological activity like myoclonus.

Eligibility and Restrictions for Use

Population Eligibility and Restrictions for Stamin

The official regulatory documentation for Stamin (Piracetam) strictly defines the populations who can and cannot use the medicine.

Contraindicated Populations (Must Not Use)

Use is strictly contraindicated in patients with certain severe pre-existing conditions, as outlined by regulatory authorities. These exclusions include severe renal impairment (creatinine clearance less than 20 mL/min or end-stage renal disease), a history of cerebral haemorrhage, and Huntington's chorea. Patients with a known hypersensitivity to piracetam or other pyrrolidone derivatives must also not use the medication.

Use in Special Populations

Official labeling places restrictions or mandates caution for several other population groups. For elderly patients and those with mild to moderate renal impairment, use is conditional, based on regular evaluation of kidney function. Due to the drug's effect on bleeding, caution is recommended for patients with underlying bleeding disorders or a history of severe haemorrhage, and those scheduled for major surgery.

Stamin is generally not recommended during pregnancy or breastfeeding, as the drug crosses the placental barrier and is excreted in human milk. Use in children and adolescents is generally restricted, with the medicine not recommended for those under the age of 16 for specific labeled uses.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Stamin (Piracetam) has a well-defined interaction profile documented in regulatory sources, which emphasizes effects on coagulation and specific pharmacodynamic reactions. All statements are based strictly on official prescribing information.

Substance/Category Official Regulatory Finding
Anticoagulants (e.g., Acenocoumarol) Increases anticoagulant effect by significantly decreasing platelet aggregation, fibrinogen, and von Willebrand's factors. Requires close monitoring of prothrombin time if Stamin is discontinued.
Thyroid Hormones ( T3 + T4 extract) Concomitant use is officially associated with specific central effects, including confusion, irritability, and sleep disorder.
Antiepileptic Drugs (e.g., Carbamazepine, Phenytoin) Does not modify the peak or trough serum levels of tested antiepileptic drugs in patients on stable doses, suggesting no significant pharmacokinetic interaction.
Alcohol No effect on Piracetam serum levels; Piracetam does not modify alcohol levels.

Pharmacokinetic and General Constraints

The drug interaction potential arising from metabolic changes is considered low. This is because approximately 90% of the Piracetam dose is excreted unchanged in the urine, and in vitro data confirms no significant inhibition of major liver cytochrome P450 isoforms. No mandatory timing separation rules are specified in the official labeling. The interaction profile is mainly focused on pharmacodynamic effects, particularly those affecting hemostasis and central nervous function.

Mechanism of Action

How Stamin Works

The mechanism of Stamin (Piracetam) is defined by its pleiotropic action, involving non-specific modulation of cell properties and metabolism, particularly in compromised tissue.

Physico-Chemical Interaction with Neuronal Cell Membranes

Stamin acts as a membrane fluidity stabilizer, physically interacting with the phospholipid layer of neuronal membranes. This influences the conformation of membrane-bound ion channels and receptors, which modulates neuronal plasticity and affects the utilization kinetics of the cholinergic and glutamatergic neurotransmitter systems.

Mitochondrial Bioenergetic Stabilization

The drug stabilizes the membranes of mitochondria, influencing cellular ATP synthesis and energy balance. This mechanism contributes to the maintenance of function during exposure to metabolic stressors such as hypoxia and oxidative damage.

Modulation of Cerebral Microcirculation

A separate supporting mechanism involves the action on erythrocyte membranes, increasing the deformability of red blood cells. This facilitates the passage of blood cells through the narrow cerebral capillaries, which modulates local microcirculation and influences the distribution of metabolic resources to cerebral cells.

Dosage and Administration Information

Official Administration Guidelines for Stamin

Stamin is administered by two official routes: primarily oral (using tablets, capsules, or solution) and secondarily via the intravenous (IV) route. IV administration is reserved for situations where oral intake is clinically infeasible, such as in cases of difficulty swallowing. The overall treatment protocol is defined by specific, high-level rules for initiation, maintenance, and cessation.


Official Dosing Regimens and Frequency

Indication Context Regimen Details
High-Dose Regimens Treatment begins at 7.2 g per day and is escalated by 4.8 g every three to four days, not to exceed 24 g daily.
Lower Dose Range The typical daily dose for indications such as vertigo or cognitive symptoms is between 2.4 g and 4.8 g.
Frequency The total daily dose must be divided into two or three equal sub-doses taken throughout the day.
Intake Timing Oral formulations may be taken with or without food and must be swallowed with liquid.

Procedural and Population Requirements

Dose adjustment is a mandatory procedural step for patients with impaired kidney function. The dosage must be strictly guided by the individual's creatinine clearance (CLcr), and regular CLcr evaluation is required for older adults on long-term treatment.

Treatment must never be stopped abruptly. When discontinuation is planned, the dosage must be slowly tapered by reducing the daily amount by 1.2 g every two days to ensure a controlled cessation protocol. This defined reduction schedule governs the entire end-of-treatment phase.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Stamin

Evidence for use in Cortical Myoclonus

Research exploring Stamin for cortical myoclonus—a condition characterized by involuntary muscular contractions—primarily consists of short-term randomized controlled trials (RCTs) and open-label studies. These studies were applied in research contexts involving fluctuating or unstable symptoms, often including adolescents and adults. The majority of evidence was derived from settings where Stamin was studied for use as an add-on treatment, meaning participants were already taking other medications. Researchers examined outcomes related to physical discomfort by using specific measurement tools, such as Myoclonus Scores, to monitor the intensity and variability of these muscular symptoms.

Evidence for use in Chronic Vertigo and Disequilibrium

Stamin was evaluated in studies for chronic or recurrent vertigo and associated feelings of disequilibrium. The research included controlled trials and double-blind studies where Stamin was compared against either a placebo or another active treatment. Researchers in these trials assessed outcomes related to systemic or functional imbalance by monitoring the frequency and intensity of vertigo episodes and measuring patients' balance and equilibrium. The body of research was used to support the indication, with data often focused on measuring symptom patterns.


Evidence for use in Age-Related Cognitive Symptoms

Research on Stamin for age-related cognitive symptoms, such as difficulties with attention and short-term memory, was studied for in various trials, including meta-analyses of existing randomized controlled trials. These studies primarily explored the effects in older adults (e.g., 50–89 years) experiencing mild cognitive deterioration or psych-organic symptoms. Findings were mixed across the analyzed studies. The evidence for this application is generally considered to have low certainty.

What is Still Uncertain in the Research Landscape

There are considerable research limitations across multiple indications. A consistent issue across many studies is that the sample sizes were modest, and many of the key trials are older. Data on long-term effects across all studied indications remain limited, and the durability of the findings is not fully established by the existing body of evidence. These limitations contribute to the general observation that certainty remains low for many of the evidence findings.

Frequently Asked Questions (FAQ)

Common questions about Stamin (FAQ)

Q: What is the average duration of Stamin's effect?

The action of the active ingredient (Piracetam) is described based on its half-life in the body. According to official pharmacokinetic information, the plasma half-life is about 5 hours, while the half-life in the cerebrospinal fluid is around 8 hours. This time frame indicates how quickly the body processes and clears the medicine.

Q: What should I do if I forget to take a dose of Stamin?

Official patient information leaflets describe the typical procedure for a forgotten dose. The procedure described is often to take the dose as soon as remembered, unless it is close to the time for your next scheduled dose. If that is the case, the usual guidance is to skip the missed dose entirely and continue with the regular schedule. Patients are instructed not to take a double dose to make up for a forgotten one.

Q: Is it okay to use Stamin if I have liver problems?

Official regulatory documents usually focus on kidney function when discussing dose adjustments, as the drug is primarily processed by the kidneys. Generally, no dosage adjustment is specifically recommended for patients with liver impairment. However, official prescribing information may advise caution or list hepatic issues as a contraindication in certain specific contexts.

Q: Does Stamin interact with pain relievers like Tylenol (acetaminophen)?

Official data suggests a low potential for Stamin to interact with many common medicines, including non-prescription pain relievers like acetaminophen. This is because the drug is mostly excreted unchanged by the kidneys and does not significantly interfere with the liver enzymes responsible for processing most other drugs.

Q: Can Stamin affect my blood pressure?

The documented side effect profile for Stamin includes reported cardiovascular effects, though they are not classified as common. Official safety data mentions events like slow heart rate (bradycardia) and dizziness upon standing (orthostatic hypotension). While direct high or low blood pressure is not commonly listed, these effects are related to the circulatory system.

Q: Can Stamin be taken with vitamins or supplements?

The official interaction profile of Stamin is considered low risk for metabolic interactions with general vitamins and mineral supplements. This is because the drug is mainly excreted by the kidneys and bypasses the major liver enzyme systems used by most supplements. However, regulatory caution suggests that highly concentrated herbal supplements may require specific review due to limited formal testing.

Q: Is Stamin approved by the FDA?

The regulatory status of the active ingredient, Piracetam, varies significantly across the world. In the United States, official records show that the drug is currently not approved by the U.S. Food and Drug Administration (FDA) for any medical use or as a dietary supplement.

Q: Can Stamin be crushed or split?

Regulatory information states that oral tablets are intended to be swallowed whole with liquid. This is due in part to the taste of the active ingredient. Licensed liquid forms are generally available if the patient is unable to swallow the tablet whole.

Q: Is Stamin only for severe cases of [condition it treats]?

Official regulatory documents and clinical trials show that Stamin has been studied and used for a range of severity levels. Indications include managing mild cognitive deterioration and chronic vertigo. Therefore, its use is not limited strictly to only the most severe conditions.

Q: How long after stopping Stamin does it stay in my system?

Official pharmacokinetic data describes how long the active ingredient stays in the body. The plasma half-life is approximately 5 hours, and it is around 8 hours in the cerebrospinal fluid. The majority of the drug is processed and excreted by the kidneys within 30 hours of administration.

Q: Why is Stamin restricted in some countries?

The different regulatory status in various countries is based on diverse national scheduling decisions by drug authorities. Some international authorities classify Piracetam as a prescription-only medicine due to its effects on the central nervous system.

Q: Are there different strengths of Stamin available?

Yes, there are different dosage strengths officially available for Stamin's oral forms. Common strengths described in official pharmaceutical documents include 800 mg and 1200 mg tablets and capsules, in addition to an oral solution.

Q: Is Stamin a habit-forming drug?

The official safety profile does not classify Stamin as a controlled substance and does not describe a potential for dependence or habit formation. However, regulatory instructions mandate that treatment must be reduced gradually (tapered) to avoid potential symptom rebound upon cessation.

Q: Is Stamin a short-term or long-term medication?

Official guidance suggests that the duration of treatment is conditional upon the underlying cerebral disease being managed. For ongoing conditions, treatment is often maintained as long as the disease persists. For acute management, official documents suggest re-evaluating the need to continue treatment every six months.

Q: Does Stamin interact with supplements like St. John's Wort?

The risk of a drug-to-drug interaction with herbal supplements like St. John's Wort is considered low based on regulatory data. This is because the active ingredient is primarily excreted by the kidneys and does not significantly interfere with the key liver enzymes (CYP450) affected by St. John's Wort.

Q: Is Stamin for acute or chronic conditions?

Official regulatory indications confirm that Stamin is used for both short-term and ongoing conditions. The drug is officially used for the treatment of certain chronic conditions, such as chronic vertigo, and has also been used in the management of acute episodes, such as in cortical myoclonus.

How should Stamin be stored and disposed of?

How to Store and Dispose of Stamin?

Official regulatory guidelines define specific requirements for the storage and disposal of Stamin (Piracetam) to ensure product stability and safety.

Storing the Medication

Stamin must be stored in a cool and dry place at a temperature below 30°C (86°F). It is mandatory to keep the product in its original packaging and ensure the container is tightly closed. The injectable solution form is specifically prohibited from being frozen. Crucially, the medication must be kept out of the sight and reach of children and pets, regardless of its form.

Disposal Instructions

Official disposal guidance recommends utilizing community drug take-back programs as the best option for discarding unused or expired Stamin. Authorities advise against flushing the medicine down the toilet or sink. If no take-back program is available, the product should be removed from its container, mixed with an undesirable substance (such as cat litter or used coffee grounds), placed in a sealed bag, and then thrown into the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stamin found in:

A-Z Index: